2 results match your criteria: "University Hospital Center and Medical School University of Zagreb[Affiliation]"
CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
Clin Lymphoma Myeloma
April 2009
Division of Hematology, Department of Medicine, University Hospital Center and Medical School University of Zagreb, Croatia.
Background: CD43 is a transmembrane glycoprotein expressed in different hematopoietic cells, including some subsets of B lymphocytes. About a quarter of diffuse large B-cell lymphomas (DLBCLs) express CD43, but its prognostic significance is unknown.
Patients And Methods: We analyzed the prognostic effect of immunohistochemically determined CD43 expression in 119 patients with newly diagnosed DLBCL.
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
Haematologica
July 2007
Division of Hematology, Department of Internal Medicine, University Hospital Center and Medical School University of Zagreb, Croatia.
We investigated the association ofFcgammaRIIIaa and FcgRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcgammaRIIIa and FcgRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcgammaRIIIa and FcgammaRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.
View Article and Find Full Text PDF